Stryker (SYK) Competitors

Stryker currently has a consensus target price of $395.48, indicating a potential upside of 39.82%. Boston Scientific has a consensus target price of $93.91, indicating a potential upside of 76.10%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Stryker.

Stryker has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

In the previous week, Stryker had 3 more articles in the media than Boston Scientific. MarketBeat recorded 28 mentions for Stryker and 25 mentions for Boston Scientific. Stryker's average media sentiment score of 0.94 beat Boston Scientific's score of 0.66 indicating that Stryker is being referred to more favorably in the media.

Stryker has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 0.3% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Boston Scientific has a net margin of 17.29% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Boston Scientific's return on equity.

Cardinal Health has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

In the previous week, Stryker had 10 more articles in the media than Cardinal Health. MarketBeat recorded 28 mentions for Stryker and 18 mentions for Cardinal Health. Stryker's average media sentiment score of 0.94 beat Cardinal Health's score of 0.92 indicating that Stryker is being referred to more favorably in the news media.

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.1% of Cardinal Health shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Stryker has a net margin of 13.20% compared to Cardinal Health's net margin of 0.62%. Stryker's return on equity of 23.42% beat Cardinal Health's return on equity.

Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 1.1%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.2%. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Stryker pays out 40.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has increased its dividend for 29 consecutive years and Stryker has increased its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has lower revenue, but higher earnings than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Cardinal Health currently has a consensus target price of $241.80, indicating a potential upside of 32.40%. Stryker has a consensus target price of $395.48, indicating a potential upside of 39.82%. Given Stryker's higher probable upside, analysts plainly believe Stryker is more favorable than Cardinal Health.

Stryker has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Stryker presently has a consensus price target of $395.48, suggesting a potential upside of 39.82%. Cencora has a consensus price target of $380.25, suggesting a potential upside of 46.27%. Given Cencora's stronger consensus rating and higher probable upside, analysts plainly believe Cencora is more favorable than Stryker.

Stryker has a net margin of 13.20% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Stryker's return on equity.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.2%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.9%. Stryker pays out 40.7% of its earnings in the form of a dividend. Cencora pays out 18.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 32 consecutive years and Cencora has increased its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

77.1% of Stryker shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 0.4% of Cencora shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cencora had 22 more articles in the media than Stryker. MarketBeat recorded 50 mentions for Cencora and 28 mentions for Stryker. Stryker's average media sentiment score of 0.94 beat Cencora's score of 0.41 indicating that Stryker is being referred to more favorably in the media.

DaVita has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Stryker has a net margin of 13.20% compared to DaVita's net margin of 5.65%. Stryker's return on equity of 23.42% beat DaVita's return on equity.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

DaVita currently has a consensus price target of $199.17, suggesting a potential upside of 0.15%. Stryker has a consensus price target of $395.48, suggesting a potential upside of 39.82%. Given Stryker's stronger consensus rating and higher possible upside, analysts clearly believe Stryker is more favorable than DaVita.

90.1% of DaVita shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 1.5% of DaVita shares are owned by company insiders. Comparatively, 4.6% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, DaVita had 8 more articles in the media than Stryker. MarketBeat recorded 36 mentions for DaVita and 28 mentions for Stryker. Stryker's average media sentiment score of 0.94 beat DaVita's score of 0.87 indicating that Stryker is being referred to more favorably in the news media.